KALA BIO announced that Todd Bazemore has been named President and Chief Executive Officer, CEO, of KALA BIO and appointed to the Board of Directors. Bazemore has served as KALA’s interim CEO since February 2025 and previously served as KALA’s President and Chief Operating Officer, COO.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Optimistic Buy Rating for Kala Pharmaceuticals Driven by KPI-012 Trial Prospects and Financial Viability
- Kala Pharmaceuticals Reports Q2 2025 Financial Results
- Kala Pharmaceuticals reports Q2 EPS ($1.71) vs ($3.16)
- Kala Pharmaceuticals initiated with a Buy at Ladenburg
- Promising Developments and Market Potential for Kala Pharmaceuticals’ KPI-012 Amidst Clinical and Regulatory Challenges